R

RenovoRx
D

RNXT

1.03000
USD
-0.09
(-8.04%)
مغلق
حجم التداول
619
الربح لكل سهم
-0
العائد الربحي
-
P/E
-2
حجم السوق
36,632,210
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
الأخبار
المقالات

العنوان: RenovoRx

القطاع: Healthcare
الصناعة: Biotechnology
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.